ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

MNPR Monopar Therapeutics Inc

0,734
0,074 (11,21%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Monopar Therapeutics Inc MNPR NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,074 11,21% 0,734 01:11:34
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,67 0,6433 0,7624 0,7272 0,66
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
18.4.202414:00GLOBEMonopar Announces Radiopharma Presentation Selected for..
16.4.202414:00GLOBEMonopar Announces Filing of Patent Protecting MNPR-101..
10.4.202414:00GLOBEMonopar Initiates Radiopharma Phase 1 Clinical Trial for..
28.3.202412:00GLOBEMonopar Reports Fourth Quarter and Full-Year 2023 Financial..
07.3.202414:30EDGAR2Form 8-K - Current report
05.3.202413:00EDGAR2Form 8-K - Current report
05.3.202413:00GLOBEMonopar Announces Positive Preclinical Therapeutic Isotope..
28.2.202419:45EDGAR2Form 8-K - Current report
27.2.202413:00GLOBEMonopar Provides Update on MNPR-101-Zr Radiopharma Clinical..
27.2.202412:59EDGAR2Form 8-K - Current report
22.2.202413:00EDGAR2Form 8-K - Current report
22.2.202413:00GLOBEMonopar Announces Promising Preclinical Data for its..
20.2.202414:00EDGAR2Form 8-K - Current report
20.2.202414:00GLOBEMonopar Receives Clearance to Proceed with First-in-Human..
04.1.202401:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202401:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.11.202313:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.11.202313:00EDGAR2Form 8-K - Current report
09.11.202313:00GLOBEMonopar Therapeutics Reports Third Quarter 2023 Financial..
01.11.202312:00EDGAR2Form 8-K - Current report
01.11.202312:00GLOBEMonopar Presents Data Showing Tumor Reduction Benefit of..
10.10.202313:00GLOBEMonopar to Participate in the Roth MKM 2023 Healthcare..
04.10.202301:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.10.202301:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.9.202313:00GLOBEMonopar to Participate in the H.C. Wainwright 25th Annual..
30.8.202323:16EDGAR2Form 8-K - Current report
10.8.202313:00EDGAR2Form 8-K - Current report
10.8.202313:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.8.202313:00GLOBEMonopar Therapeutics Reports Second Quarter 2023 Financial..
08.8.202313:00EDGAR2Form 8-K - Current report
08.8.202313:00GLOBEMonopar Provides Encouraging Camsirubicin Clinical Data..
11.7.202313:00EDGAR2Form 8-K - Current report
11.7.202313:00GLOBEMonopar Announces MNPR-101 Radiopharma Collaboration..
04.7.202300:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.7.202300:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.6.202322:13EDGAR2Form 8-K - Current report
21.6.202313:00GLOBEMonopar to Participate in the Radiopharma Forum by the Lake..
14.6.202313:00GLOBEMonopar to Participate in the Maxim Group’s Healthcare..
01.6.202313:00GLOBEMonopar Announces Encouraging Camsirubicin Phase 1b Trial..
11.5.202313:00GLOBEMonopar Therapeutics Reports First Quarter 2023 Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock